"On Tuesday, Nov. 30, the Antimicrobial Drugs Advisory Committee members voted whether the potential benefits of the oral drug molnupiravir outweigh the potential risks, based on safety and efficacy data from clinical trials.
Thirteen members voted in favor of recommending authorization, while the remaining 10 members voted against authorization...Read all.
No comments:
Post a Comment